A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies.
paper
Cited
Public
- Authors
- Piper, Megan E; Smith, Stevens S; Schlam, Tanya R; Fiore, Michael C; Jorenby, Douglas E; Fraser, David; Baker, Timothy B
- Year
- 2009
- Journal
- Archives of general psychiatry
- PMID
- 19884613
- DOI
- 10.1001/archgenpsychiatry.2009.142
- PMCID
- PMC2933113
CONTEXT: Little direct evidence exists on the relative efficacies of different smoking cessation pharmacotherapies, yet such evidence is needed to make informed decisions about their clinical use. OBJECTIVE: To assess the relative efficacies of 5 smoking cessation pharmacotherapy interventions using placebo-controlled, head-to-head comparisons. DESIGN: A randomized, double-blind, placebo-controlled clinical trial. SETTING: Two urban research sites. PATIENTS: One thousand five hundred four adults who smoked at least 10 cigarettes per day during the past 6 months and reported being motivated to quit smoking. Participants were excluded if they reported using any form of tobacco other than cigarettes; current use of bupropion; having a current psychosis or schizophrenia diagnosis; or having medical contraindications for any of the study medications. INTERVENTIONS: Participants were randomized to 1 of 6 treatment conditions: nicotine lozenge, nicotine patch, sustained-release bupropion, nicotine patch plus nicotine lozenge, bupropion plus nicotine lozenge, or placebo. In addition, all participants received 6 individual counseling sessions. MAIN OUTCOME MEASURES: Biochemically confirmed 7-day point-prevalence abstinence assessed at 1 week after the quit date (postquit), end of treatment (8 weeks postquit), and 6 months postquit. Other outcomes were initial cessation, number of days to lapse, number of days to relapse, and latency to relapse after the first lapse. RESULTS: All pharmacotherapies differed from placebo when examined without protection for multiple comparisons (odds ratios, 1.63-2.34). With such protection, only the nicotine patch plus nicotine lozenge (odds ratio, 2.34, P < .001) produced significantly higher abstinence rates at 6-month postquit than did placebo. CONCLUSION: While the nicotine lozenge, bupropion, and bupropion plus lozenge produced effects that were comparable with those reported in previous research, the nicotine patch plus lozenge produced the greatest benefit relative to placebo for smoking cessation.
No figures extracted from this document.
1–20 of 39
Next →
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Efficacy of combined nicotine replacement therapy (NRT) and bupropion compared to bupropion alone for smoking cessation: a systematic review and meta-analysis. | Wang M et al. | — | 2026 | → |
| Expanding the scope of the withdrawal syndrome: Anhedonia as a core nicotine withdrawal symptom. | Betts JM et al. | — | 2025 | → |
| Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024. | Seo YB et al. | — | 2025 | → |
| Testing oral nicotine pouches versus nicotine replacement therapy for cigarette harm reduction in Appalachia: The ARISE study protocol. | Wermert A et al. | — | 2025 | → |
| Exploring Racial/Ethnic Disparities in Substance Dependence and Serious Psychological Distress among US Veterans. | Lawson SC et al. | — | 2024 | → |
| Primary prevention of cardiovascular disease in women. | Gray MP et al. | — | 2024 | → |
| Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement: A Randomized Clinical Trial. | Cinciripini PM et al. | — | 2024 | → |
| Tobacco Quitline Retreatment Interventions Among Adults With Socioeconomic Disadvantage: A Factorial Randomized Clinical Trial. | Kaye JT et al. | — | 2024 | → |
| What to do after smoking relapse? A sequential multiple assignment randomized trial of chronic care smoking treatments. | Schlam TR et al. | — | 2024 | → |
| Acute nicotine abstinence amplifies subjective withdrawal symptoms and threat-evoked fear and anxiety, but not extended amygdala reactivity. | Kim HC et al. | — | 2023 | → |
| Antidepressants for smoking cessation. | Hajizadeh A et al. | — | 2023 | → |
| Biochemical validation of self-reported electronic nicotine delivery system and tobacco heaviness of use. | Addicott MA et al. | — | 2023 | → |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | Theodoulou A et al. | — | 2023 | → |
| Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment. | Chen LS et al. | — | 2023 | → |
| Leveraging Implementation Science in the Treatment of Tobacco Use Disorder. | Ramsey AT et al. | — | 2023 | → |
| The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. | Guo K et al. | — | 2022 | → |
| The Promise of Polygenic Risk Prediction in Smoking Cessation: Evidence From Two Treatment Trials. | Bray M et al. | — | 2022 | → |
| Time-Varying Mediation of Pharmacological Smoking Cessation Treatments on Smoking Lapse via Craving, Cessation Fatigue, and Negative Mood. | Chakraborti Y et al. | — | 2022 | → |
| Barriers to Building More Effective Treatments: Negative Interactions Amongst Smoking Intervention Components. | Baker TB et al. | — | 2021 | → |
| Comparative effects of varenicline or combination nicotine replacement therapy versus patch monotherapy on candidate mediators of early abstinence in a smoking cessation attempt. | Kim N et al. | — | 2021 | → |
| Effectiveness and Safety Profile of Alternative Tobacco and Nicotine Products for Smoking Reduction and Cessation: A Systematic Review. | Zakiyah N et al. | — | 2021 | → |
| Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. | McClure EA et al. | — | 2021 | → |
| Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial. | Sibul F et al. | — | 2021 | → |
| Interventions for preventing weight gain after smoking cessation. | Hartmann-Boyce J et al. | — | 2021 | → |
| Multiethnic Prediction of Nicotine Biomarkers and Association With Nicotine Dependence. | Bergen AW et al. | — | 2021 | → |
| Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. | Thomas KH et al. | — | 2021 | → |
| Temporal networks of tobacco withdrawal symptoms during smoking cessation treatment. | Lydon-Staley DM et al. | — | 2021 | → |
| Antidepressants for smoking cessation. | Howes S et al. | — | 2020 | → |
| Anxiety Sensitivity and Distress Tolerance in Smokers: Relations With Tobacco Dependence, Withdrawal, and Quitting Success†. | Schlam TR et al. | — | 2020 | → |
| Current cannabis use and smoking cessation among treatment seeking combustible smokers. | Rogers AH et al. | — | 2020 | → |
| Finite Mixture Models with Student t Distributions: an Applied Example. | Burgess-Hull AJ | — | 2020 | → |
| Longitudinal effects of smoking cessation on carotid artery atherosclerosis in contemporary smokers: The Wisconsin Smokers Health Study. | Stein JH et al. | — | 2020 | → |
| Multiethnic Prediction of Nicotine Biomarkers and Association with Nicotine Dependence | Bergen AW et al. | — | 2020 | — |
| Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. | Giulietti F et al. | — | 2020 | → |
| Playing Around with Quitting Smoking: A Randomized Pilot Trial of Mobile Games as a Craving Response Strategy. | Schlam TR et al. | — | 2020 | → |
| Psychiatric comorbidities in a comparative effectiveness smoking cessation trial: Relations with cessation success, treatment response, and relapse risk factors. | Johnson AL et al. | — | 2020 | → |
| Searching for Personalized Medicine for Binge Drinking Smokers: Smoking Cessation Using Varenicline, Nicotine Patch, or Combination Nicotine Replacement Therapy. | Kaye JT et al. | — | 2020 | → |
| The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS). | Albertson TE et al. | — | 2020 | → |
| Variants in the CHRNA5-CHRNA3-CHRNB4 Region of Chromosome 15 Predict Gastrointestinal Adverse Events in the Transdisciplinary Tobacco Use Research Center Smoking Cessation Trial. | Culverhouse RC et al. | — | 2020 | → |
| "Cold turkey" or pharmacotherapy: Examination of tobacco cessation methods tried among smokers prior to developing head and neck cancer. | Khariwala SS et al. | — | 2019 | → |
| Combined nicotine patch with gum versus nicotine patch alone in smoking cessation in Hong Kong primary care clinics: a randomised controlled trial. | Leung MKW et al. | — | 2019 | → |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | Lindson N et al. | — | 2019 | → |
| Enhancing Behavior Change Technique Coding Methods: Identifying Behavioral Targets and Delivery Styles in Smoking Cessation Trials. | Black N et al. | — | 2019 | → |
| Longitudinal Effects of Cigarette Smoking and Smoking Cessation on Aortic Wave Reflections, Pulse Wave Velocity, and Carotid Artery Distensibility. | Schmidt KMT et al. | — | 2019 | → |
| Modelling continuous abstinence rates over time from clinical trials of pharmacological interventions for smoking cessation. | Jackson SE et al. | — | 2019 | → |
| Strain-specific altered nicotine metabolism in 3,3'-diindolylmethane (DIM) exposed mice. | Bloom AJ et al. | — | 2019 | → |
| The effects of transcranial direct current stimulation compared to standard bupropion for the treatment of tobacco dependence: A randomized sham-controlled trial. | Ghorbani Behnam S et al. | — | 2019 | → |
| Echogenicity of the carotid arterial wall in active smokers. | Mitchell C et al. | — | 2018 | → |
| Extreme Response Style and the Measurement of Intra-Individual Variability in Affect. | Deng S et al. | — | 2018 | → |
| [Interventions for smoking cessation in 2018]. | Abdul-Kader J et al. | — | 2018 | → |
| Nicotine dependence is associated with functional variation in FMO3, an enzyme that metabolizes nicotine in the brain. | Teitelbaum AM et al. | — | 2018 | → |
| Nicotine replacement therapy versus control for smoking cessation. | Hartmann-Boyce J et al. | — | 2018 | → |
| Pharmacological Therapy of COPD: Reasons for Optimism. | Celli BR | — | 2018 | → |
| The social networks of smokers attempting to quit: An empirically derived and validated classification. | Burgess-Hull AJ et al. | — | 2018 | → |
| The Value of Biosamples in Smoking Cessation Trials: A Review of Genetic, Metabolomic, and Epigenetic Findings. | Saccone NL et al. | — | 2018 | → |
| Use of hormonal contraceptives and smoking cessation: A preliminary report. | Allen AM et al. | — | 2018 | → |
| Use of polygenic risk scores of nicotine metabolism in predicting smoking behaviors. | Chen LS et al. | — | 2018 | → |
| Anhedonia: Its Dynamic Relations With Craving, Negative Affect, and Treatment During a Quit Smoking Attempt. | Cook JW et al. | — | 2017 | → |
| Benefits of varenicline vs. bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. | Cinciripini PM et al. | — | 2017 | → |
| Cigarette smoking and depression comorbidity: systematic review and proposed theoretical model. | Mathew AR et al. | — | 2017 | → |
| Combination nicotine replacement therapy: strategies for initiation and tapering. | Hsia SL et al. | — | 2017 | → |
| Effect of exercise type on smoking cessation: a meta-analysis of randomized controlled trials. | Klinsophon T et al. | — | 2017 | → |
| Evaluating the effect of smoking cessation treatment on a complex dynamical system. | Bekiroglu K et al. | — | 2017 | → |
| Implementation of a tobacco-free workplace program at a local mental health authority. | Correa-Fernández V et al. | — | 2017 | → |
| Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers. | Schuit E et al. | — | 2017 | → |
| Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. | Smith PH et al. | — | 2017 | → |
| Study of monotherapy versus combination therapy for tobacco dependence among heavily addicted smokers. | Ternullo SR et al. | — | 2017 | → |
| What a difference a day makes: differences in initial abstinence response during a smoking cessation attempt. | Piper ME et al. | — | 2017 | → |
| An Open Trial of Electronic Cigarettes for Smoking Cessation Among Methadone-Maintained Smokers. | Stein MD et al. | — | 2016 | → |
| Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. | Baker TB et al. | — | 2016 | → |
| Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. | Tulloch HE et al. | — | 2016 | → |
| Non-pharmacological treatments for COPD. | Mulhall P et al. | — | 2016 | → |
| [Psychotherapy and pharmacotherapy for harmful tobacco use and tobacco dependency]. | Batra A et al. | — | 2016 | → |
| Randomized trials are frequently fragmented in multiple secondary publications. | Ebrahim S et al. | — | 2016 | → |
| Reduction of nicotine self-administration by chronic nicotine infusion with H1 histamine blockade in female rats. | Levin ED et al. | — | 2016 | → |
| Repeated measures latent class analysis of daily smoking in three smoking cessation studies. | McCarthy DE et al. | — | 2016 | → |
| Transitions in Smokers' Social Networks After Quit Attempts: A Latent Transition Analysis. | Bray BC et al. | — | 2016 | → |
| A Comprehensive Approach to Tobacco Dependence Interventions. | Baldassarri SR et al. | — | 2015 | → |
| Anhedonia as a component of the tobacco withdrawal syndrome. | Cook JW et al. | — | 2015 | → |
| An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. | Celli BR et al. | — | 2015 | → |
| An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. | Celli BR et al. | — | 2015 | → |
| Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date. | Mamoun M et al. | — | 2015 | → |
| Defining and predicting short-term alcohol use changes during a smoking cessation attempt. | Berg KM et al. | — | 2015 | → |
| Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. | Bergen AW et al. | — | 2015 | → |
| Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. | Chen LS et al. | — | 2015 | → |
| Olfactory cue reactivity in nicotine-dependent adult smokers. | Cortese BM et al. | — | 2015 | → |
| Paths to tobacco abstinence: A repeated-measures latent class analysis. | McCarthy DE et al. | — | 2015 | → |
| Predicting use of assistance when quitting: a longitudinal study of the role of quitting beliefs. | Myers MG et al. | — | 2015 | → |
| The effect of switching pharmacological intervention during extinction on nicotine-evoked conditioned responding in rats. | Pittenger ST et al. | — | 2015 | → |
| The fMRI BOLD response to unisensory and multisensory smoking cues in nicotine-dependent adults. | Cortese BM et al. | — | 2015 | → |
| Treatment of tobacco use disorders in smokers with serious mental illness: toward clinical best practices. | Evins AE et al. | — | 2015 | → |
| Addressing the evidence for FDA nicotine replacement therapy label changes: a policy statement of the Association for the Treatment of Tobacco use and Dependence and the Society for Research on Nicotine and Tobacco. | Fucito LM et al. | — | 2014 | → |
| A Hybrid Model Predictive Control Strategy for Optimizing a Smoking Cessation Intervention. | Timms KP et al. | — | 2014 | → |
| Anhedonia, depressed mood, and smoking cessation outcome. | Leventhal AM et al. | — | 2014 | → |
| Beyond cigarettes per day. A genome-wide association study of the biomarker carbon monoxide. | Bloom AJ et al. | — | 2014 | → |
| Bupropion-SR for smoking reduction and cessation in alcohol-dependent outpatients: a naturalistic, open-label study. | Karam-Hage M et al. | — | 2014 | → |
| CHRNA5 variant predicts smoking cessation in patients with acute myocardial infarction. | Chen LS et al. | — | 2014 | → |
| Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review. | Weinberger AH et al. | — | 2014 | → |
| Early quit days among methadone-maintained smokers in a smoking cessation trial. | de Dios MA et al. | — | 2014 | → |
| Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial. | Tulloch H et al. | — | 2014 | → |
| Integrating a Behavioural Sleep Intervention into Smoking Cessation Treatment for Smokers with Insomnia: A Randomised Pilot Study. | Fucito LM et al. | — | 2014 | → |
| Interplay of genetic risk (CHRNA5) and environmental risk (partner smoking) on cigarette smoking reduction. | Chen LS et al. | — | 2014 | → |
| "Meaningful use" provides a meaningful opportunity. | Rabius V et al. | — | 2014 | → |
| Organic cation transporter variation and response to smoking cessation therapies. | Bergen AW et al. | — | 2014 | → |
| Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). | Chen LS et al. | — | 2014 | → |
| Predictors of success for smoking cessation at the workplace: a longitudinal study. | Stolz D et al. | — | 2014 | → |
| Smokers' physical activity and weight gain one year after a successful versus unsuccessful quit attempt. | Gennuso KP et al. | — | 2014 | → |
| Smoking cessation. | Rennard SI et al. | — | 2014 | → |
| Smoking cessation and the risk of diabetes mellitus and impaired fasting glucose: three-year outcomes after a quit attempt. | Stein JH et al. | — | 2014 | → |
| Smoking cessation in smokers who smoke menthol and non-menthol cigarettes. | Smith SS et al. | — | 2014 | → |
| Time-varying processes involved in smoking lapse in a randomized trial of smoking cessation therapies. | Vasilenko SA et al. | — | 2014 | → |
| Tobacco use and cessation for cancer survivors: an overview for clinicians. | Karam-Hage M et al. | — | 2014 | → |
| Tobacco use treatment in primary care patients with psychiatric illness. | Cerimele JM et al. | — | 2014 | → |
| Using mixture models with known class membership to address incomplete covariance structures in multiple-group growth models. | Kim SY et al. | — | 2014 | → |
| Variants in two adjacent genes, EGLN2 and CYP2A6, influence smoking behavior related to disease risk via different mechanisms. | Bloom AJ et al. | — | 2014 | → |
| A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self-administration. | Udo T et al. | — | 2013 | → |
| Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. | Carpenter MJ et al. | — | 2013 | → |
| Early lapses in a cessation attempt: lapse contexts, cessation success, and predictors of early lapse. | Deiches JF et al. | — | 2013 | → |
| Electrocardiographic changes associated with smoking and smoking cessation: outcomes from a randomized controlled trial. | Gepner AD et al. | — | 2013 | → |
| Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. | Smith SS et al. | — | 2013 | → |
| Interventions for tobacco smoking. | Schlam TR et al. | — | 2013 | → |
| Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. | Bergen AW et al. | — | 2013 | → |
| Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems. | Shahab L et al. | — | 2013 | → |
| Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study. | Saquib N et al. | — | 2013 | → |
| Short-term effectiveness of smoking-cessation treatment on respiratory function and CEA level. | Pezzuto A et al. | — | 2013 | → |
| Smoking cessation in patients with respiratory disease: existing treatments and future directions. | Rigotti NA | — | 2013 | → |
| Smoking cessation interventions for smokers with current or past depression. | van der Meer RM et al. | — | 2013 | → |
| The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. | Forey BA et al. | — | 2013 | → |
| Understanding the role of cessation fatigue in the smoking cessation process. | Liu X et al. | — | 2013 | → |
| Up in smoke? A preliminary open-label trial of nicotine replacement therapy and cognitive behavioral motivational enhancement for smoking cessation among youth in Los Angeles. | Swanson AN et al. | — | 2013 | → |
| Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. | Stein MD et al. | — | 2013 | → |
| An ecological momentary assessment analysis of prequit markers for smoking-cessation failure. | Yeh VM et al. | — | 2012 | → |
| Effects of smoking and cessation on subclinical arterial disease: a substudy of a randomized controlled trial. | Johnson HM et al. | — | 2012 | → |
| Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success. | Chen LS et al. | — | 2012 | → |
| Interventions for preventing weight gain after smoking cessation. | Farley AC et al. | — | 2012 | → |
| Isolating the role of psychological dysfunction in smoking cessation: relations of personality and psychopathology to attaining cessation milestones. | Leventhal AM et al. | — | 2012 | → |
| Life 1 year after a quit attempt: real-time reports of quitters and continuing smokers. | Schlam TR et al. | — | 2012 | → |
| Long-term effects of smoking and smoking cessation on exercise stress testing: three-year outcomes from a randomized clinical trial. | Asthana A et al. | — | 2012 | → |
| Nicotine replacement therapy for smoking cessation. | Stead LF et al. | — | 2012 | → |
| Pharmacologic agents for tobacco dependence treatment: 2011 update. | Hays JT et al. | — | 2012 | → |
| Pharmacologic approaches to smoking cessation. | Bailey AM et al. | — | 2012 | → |
| Relations of alcohol consumption with smoking cessation milestones and tobacco dependence. | Cook JW et al. | — | 2012 | → |
| Role of behavioral medicine in primary care. | Feldman MD et al. | — | 2012 | → |
| Should all smokers use combination smoking cessation pharmacotherapy? Using novel analytic methods to detect differential treatment effects over 8 weeks of pharmacotherapy. | Loh WY et al. | — | 2012 | → |
| Smoking cessation and quality of life: changes in life satisfaction over 3 years following a quit attempt. | Piper ME et al. | — | 2012 | → |
| Strategies to help a smoker who is struggling to quit. | Rigotti NA | — | 2012 | → |
| Why two smoking cessation agents work better than one: role of craving suppression. | Bolt DM et al. | — | 2012 | → |
| Abstinence and psychological distress in co-morbid smokers using various pharmacotherapies. | Steinberg MB et al. | — | 2011 | → |
| Ambulatory activity associations with cardiovascular and metabolic risk factors in smokers. | Julius BR et al. | — | 2011 | → |
| An electronic decision support system to motivate people with severe mental illnesses to quit smoking. | Brunette MF et al. | — | 2011 | → |
| Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. | Piper ME et al. | — | 2011 | → |
| Clinical practice. Treating smokers in the health care setting. | Fiore MC et al. | — | 2011 | → |
| Cognitive conflict following appetitive versus negative cues and smoking cessation failure. | Schlam TR et al. | — | 2011 | → |
| Effects of exogenous agents on brain development: stress, abuse and therapeutic compounds. | Archer T | — | 2011 | → |
| Effects of smoking and smoking cessation on lipids and lipoproteins: outcomes from a randomized clinical trial. | Gepner AD et al. | — | 2011 | → |
| Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. | Chacón F et al. | — | 2011 | → |
| Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. | Kalman D et al. | — | 2011 | → |
| New methods for tobacco dependence treatment research. | Baker TB et al. | — | 2011 | → |
| Nicotine replacement therapies: patient safety and persistence. | Ferguson SG et al. | — | 2011 | → |
| Pharmacotherapy for smoking cessation: current advances and research topics. | Raupach T et al. | — | 2011 | → |
| Preventing lung cancer by treating tobacco dependence. | Hurt RD et al. | — | 2011 | → |
| Smoker characteristics and smoking-cessation milestones. | Japuntich SJ et al. | — | 2011 | → |
| The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. | Japuntich SJ et al. | — | 2011 | → |
| Tobacco withdrawal components and their relations with cessation success. | Piper ME et al. | — | 2011 | → |
| Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. | Mills EJ et al. | — | 2010 | → |
| Combination pharmacotherapy for stopping smoking: what advantages does it offer? | Ebbert JO et al. | — | 2010 | → |
| Comparison of available treatments for tobacco addiction. | Herman AI et al. | — | 2010 | → |
| Effects of smoking and smoking cessation on endothelial function: 1-year outcomes from a randomized clinical trial. | Johnson HM et al. | — | 2010 | → |
| Effects of smoking intensity and cessation on inflammatory markers in a large cohort of active smokers. | Asthana A et al. | — | 2010 | → |
| Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. | Piper ME et al. | — | 2010 | → |
| Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. | Buchanan L | — | 2010 | → |
| Nicotine patch plus lozenge gives greatest increases in abstinence from smoking rates at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined. | Gonzales D | — | 2010 | → |
| Pharmacotherapies for adolescent substance use disorders. | Simkin DR et al. | — | 2010 | → |
| Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. | Piper ME et al. | — | 2010 | → |
| Risk factors for subclinical carotid atherosclerosis among current smokers. | Johnson HM et al. | — | 2010 | → |
| Smoking cessation has no influence on quality of life in patients with peripheral arterial disease 5 years post-vascular surgery. | Hoogwegt MT et al. | — | 2010 | → |
| Smoking cessation-recent advances. | McNeil JJ et al. | — | 2010 | → |
| Therapeutic advances in the treatment of nicotine addiction: present and future. | Casella G et al. | — | 2010 | → |
| Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. | Altice FL et al. | — | 2010 | → |
| Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. | Smith SS et al. | — | 2009 | → |
| Obesity and smoking: comparing cessation treatment seekers with the general smoking population. | LaRowe TL et al. | — | 2009 | → |